Cognito Therapeutics Series C — Cognito Therapeutics

Cognito Therapeutics has secured $105 million in an oversubscribed Series C funding round. The company is developing its Spectris™ neuromodulation device for the treatment of Alzheimer's disease. This funding will accelerate the advancement of their platform and clinical programs.